FAR from speeding up the discovery of drugs, the sequencing of the human genome has actually slowed it down, claims a report unveiled last week.
No one doubts that information revealed by the genome will eventually help researchers develop a vast range of novel drugs, but in the short term the reverse seems to be true. “We are drowning in data,” says Martin Wales of UBS Warburg, the Swiss-based financial services company that produced the report.
“In the long run, perhaps a decade from now, we will see benefits of the genome, but at present the industry is still wrestling with how best to use the…
